. [1] [2] [3] 
Histological Grading of Central Nervous System Tumors
There are not many changes in WHO histological grading in 2016 update as compared to 2007 CNS tumor, only a new category "grade unknown" is added for diffuse leptomeningeal glioneuronal tumor. Grading of CNS tumors is mainly based on four morphologic criteria: cytological atypia, mitotic activity, microvascular proliferation (endothelial cell proliferation), and necrosis (St. Anne-Mayo grading system). According to above parameters, CNS tumors are classified in four grades. Table 2 shows the WHO histological grading of CNS tumors.
• Grade I: Tumors do not meet any of the criteria.
These tumors are slow growing, nonmalignant, and associated with long-term survival • Grade II: Tumors meet only one criterion, i.e., only cytological atypia. These tumors are slow growing but recur as higher-grade tumors. They can be malignant or nonmalignant • Grade III: Tumors meet two criteria, i.e., anaplasia and mitotic activity. These tumors are malignant and often recur as higher-grade tumors • Grade IV: Tumors meet three or four of the criteria, i.e., showing anaplasia, mitotic activity with microvascular proliferation, and/or necrosis. These tumors reproduce rapidly and are very aggressive malignant tumors. [1, 4] 
Features of 2016 World Health Organization Classification of Central Nervous System Tumors

New nomenclature
Standard terminology was introduced by combining histopathological and molecular features such as • Histopathological name followed by the genetic features, for example, diffuse astrocytoma, isocitrate dehydrogenase (IDH)-mutant and medulloblastoma, and tumors in wingless (WNT)-activated • For entities with more than one genetic determinant:
Histopathological name followed by the multiple molecular features are included in the name, for example, oligodendroglioma, IDH-mutant, and1p/19q-codeleted • For a tumor lacking a genetic mutation: The term wild type can be used, for example, glioblastoma and IDH-wild type • For laboratory lacking any access to molecular diagnostic testing, the term not otherwise specified (NOS) can be used (i.e., NOS). NOS is also applicable to tumors, in which genetic assay testing is inconclusive. An NOS designation implies that there is insufficient information to assign a most specific code • For tumor entities, in which a specific genetic alteration is present, the terms "positive" can be used is present, for example, ependymoma and RELA fusion-positive. [2] Major changes in World Health Organization central nervous system tumor classification Major changes have been introduced in the classification of two categories of tumors, based on molecular markers -diffuse gliomas (astrocytic, oligodendroglial, and glioblastoma tumors) and embryonal tumors particularly medulloblastoma.
According to new classification, the diffuse gliomas include the astrocytic tumors (WHO Grade II and III), oligodendrogliomas (WHO Grade II and III), oligoastrocytoma (WHO Grade II and III), and glioblastomas (WHO Grade IV). Earlier in 2007 classification, all astrocytic tumors had been grouped together, but now in new 2016 classification, all diffuse gliomas whether they are astrocytic or oligodendroglial are grouped under one heading, mainly based on their growth pattern, behavior as well as a mutation in IDH. This separates tumors especially astrocytomas that have more circumscribed growth, lack IDH gene alteration, or have BRAF mutation (i.e., pilocytic astrocytoma, subependymal giant cell astrocytoma, and pleomorphic xanthoastrocytoma). [5] Main molecular markers used in gliomas Isocitrate dehydrogenase Main molecular makers in gliomas are IDH, 1p19qdeletion, MGMT, TERT, ATRX and p53 which are of diagnostic significance as shown in Table 3 .
Two IDH variants have been used IDH 1 and IDH 2.
Both are an enzyme in Krebs cycle which catalyzes the conversion of isocitrate to alpha-ketoglutarate.
IDH 1 mutations are heterozygous, involving an amino acid substitution (glycine to arginine) in the active site of the enzyme in codon 132 (R132H). This mutation results in the abnormal production of 2-hydroxyglutarate which causes histone and DNA methylation, hence promoting tumorigenesis. Contd... IDH is a most important diagnostic marker as it can differentiate glioma from gliosis. It is positive in astrocytoma, oligodendroglioma, and even in 10% glioblastoma, especially secondary.
IDH can be demonstrated by IDH 1 or IDH 2 mutation by immunohistochemistry using mutation-specific antibody against R132H mutant IDH 1, if immunostaining is negative, then it should be followed by IDH 1/2 DNA genotyping.
Mutation in both IDH 1 and IDH 2 entity is known as IDH mutant. Both are negative then it is known as IDH wild type. If IDH testing is not available or cannot be fully performed or is inconclusive, then it is labeled as IDH NOS. [6, 7] 1p/19q co-deletion In 1p/19q co-deletion, there is complete deletion of both the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) . 1p/19q co-deletion can be demonstrated by fluorescent in situ hybridization (FISH), polymerase chain reaction, chromogenic in situ hybridization, or molecular genetic testing. It is definitive for the diagnosis of Grade II and Grade III (anaplastic) oligodendroglioma. It is a strong prognostic factor associated with improved survival and also a predictive factor for response to chemotherapy as well as radiotherapy.
[5]
O6-methylguanine-DNA methyltransferase methylation (MGMT)
The O 6 -methylguanine-DNA methyltransferase (MGMT) gene encodes a DNA repair enzyme that can nullify the effects of alkylating chemotherapy such as temozolomide. The alkylating chemotherapy damages DNA by adding methyl groups. Therefore, a tumor with a high degree of MGMT activity will be resistant to chemotherapies which target DNA at this location. If the promoter region of the MGMT gene is unmethylated, the gene will be active, whereas if the promoter region of MGMT is hypermethylated, the gene will be silenced. However, if the MGMT gene is active, the damage is rapidly repaired. Methylation of the MGMT gene promoter is a favorable prognostic and predictive factor in glioblastoma patients, but it is not a diagnostic marker for the same. [8] TERT (Telomerase reverse transcriptase) promoter mutations TERT mutations often involve C228T and C250T mutations of the promoter region. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas. It occurs mainly in glioblastoma and oligodendroglioma. [9, 10] Alpha-thalassemia/mental retardation syndrome X-linked (ATRX) It is chromatin remodeling protein important in DNA replication, telomere stability, gene transcription, chromosome congression, and cohesion during cell division. Alpha-thalassemia/mental retardation syndrome X-linked (ATRX) mutation results in lengthening of telomerase which helps in chromatin maintenance and remodeling. All cells are ATRX positive. If ATRX mutation is present, then there will be a loss of staining in the cells.
ATRX mutations are almost always accompanied by other mutations in the histone regulation (IDH, H33 K27M, tumor protein p53 [TP53], etc.). Loss of ATRX expression is seen in 45% of anaplastic astrocytomas, 27% of anaplastic oligoastrocytomas, and 10% of anaplastic oligodendrogliomas and also in pediatric and adult high-grade astrocytoma. [10, 11] Tumor protein p53 p53 is a tumor suppressor gene located on the short arm of chromosome 17. Loss of p53 leads to DNA damage, hypoxia, oncogene activation, microtubule disruption, and oxidative damage which in turn contributes to the CNS tumors pathogenesis mainly medulloblastoma, glioblastoma, and in 56%-58% of IDH-mutant astrocytomas. Copy number-neutral loss of heterozygosity of chromosome 17p (CNLOH 17p) was nearly exclusively associated with IDH 1 mutant astrocytomas with TP53 mutations. "CNLOH" means that one copy of the chromosomal has been deleted whereas the remaining copy has been duplicated. The net result is that the cell still has a total of two copies of the gene or chromosomal segment, but instead of having two different copies [one from the mother and one from the father], a single copy has been duplicated). CNLOH 17p was found to be a significant prognostic factor, with better survival outcomes for those with the CNLOH 17p alteration. [12, 13] 
Molecular markers used in embryonal tumors
Tumors in wingless and sonic hedgehog activation WNT-activated and sonic hedgehog active groups show activation cell signaling pathways which lead to tumorigenesis in medulloblastoma. In 2016 WHO classification update, medulloblastoma is classified according to molecular characteristics as well as histological features. Molecular classification is based on transcriptome, microRNA (miRNA), and methylome profiling for clinical treatment and histological classification has also been retained due to its clinical utility when molecular analysis is not feasible. [14] C19MC alteration Amplification of the C19MC region on chromosome 19 is noted in embryonal tumor with multilayered rosettes (ETMR). The presence of a focal amplification at chromosome region 19q13.42 associated with an upregulation of the oncogenic miRNA cluster. [15] Other new molecular markers are H3 K27M-mutation Histone H3 K27M is a mutation in the H3F3A gene, encoding for histone H3.3. The lysine is substituted to methionine at 27 position in histone variant H3.3 (H3.3-K27M). This mutation leads to a global reduction of H3K27 trimethylation by sequestering an enzymatic subunit of the polycomb repressive complex 2. As a consequence, the epigenetic setting of the cell including DNA methylation is altered and drives gene expression toward tumorigenesis. [16, 17] RELA fusion C11orf95-RELA fusions result from chromothripsis involving chromosome 11q13.1. C11orf95-RELA fusion proteins translocated spontaneously to the nucleus to activate members of the nuclear factor-κB family of transcriptional regulators that are central mediators of the cellular inflammatory response and which rapidly transform neural stem cells to form tumors, i.e., ependymoma. [18] Newly added entities, variants, and patterns • New entities have been added such as diffuse midline glioma, H3 K27M-mutant, diffuse leptomeningeal glioneuronal tumor, and ependymoma RELA-positive tumors, and some variants have been added, especially in glioblastoma such as epithelioid glioblastoma. As well as some patterns such as glioblastoma with a primitive neuroectodermal tumor (PNET) component have been included in 2016 CNS tumor classifications • Some entities, variants, and patterns have been deleted such as gliomatosis cerebri (now considered a pattern instead of an entity) and "PNET" terminology for embryonal tumors. K27M and also positive for neural cell adhesion molecule 1, S-100, OLIG2, MAP2, and Nuclear p53 Negative for Neu N and Chromogranin A • Prognosis: Prognosis: Poor. [16, 20] Diffuse leptomeningeal glioneuronal tumor (also known as disseminated oligodendroglial-like leptomeningeal tumor of childhood) [25] Integrated Reporting of Central Nervous System Tumors Now, emphasis has been laid down on integrated reporting of CNS tumous. Diagnosis should be "layered" with histological classification, WHO grade, and molecular information and reported as "integrated diagnosis." [2] • 
Advantages And Challenges Of 2016 Central Nervous System Update
Advantages
The main advantages of this classification are:
• Diagnostic criteria, pathological features, and associated genetic alterations are explained in disease-oriented manner leading to more homogenous and specific disease entities with increased objectivity • New genetically defined entities are described separately • Pediatric tumors are separated and described independently from its adult counter part • Improvement in diagnostic accuracy, patient management, and treatment response due to targeted therapies.
Challenges
Some challenges in this classification are:
• Even though molecular assays are included in diagnostic criteria, methods to obtain them have not been specified leading to interobserver as well as interinstitutional variations • Many institutions or regions still are devoid of access to genetic diagnostic tools • Adoption of tests to determine genetic alterations and increased availability of IHC markers is a time-consuming process • The term "NOS" indicates insufficient information which can create "wastebasket" category in future for research purposes • Diagnosis of oligoastrocytoma is still difficult to define as oligoastrocytoma and anaplastic oligoastrocytoma are now designated as NOS categories. Their diagnosis should be made in the absence of diagnostic molecular marker tests or in the absence of a dual genotype classification which is done • Actual format for reporting integrated diagnoses in lacking • The use of both histology and molecular features increases the possibility of incongruous results, for example, a tumor that appears astrocytic histologically but has IDH mutation, and 1p19q co-deletion would preferably be reported as oligodendroglioma as the genotype overrides the phenotype according to new classification • Even now, classification cannot proceed purely on the basis of genotype alone because WHO grading is still based on histological criteria. [1, 2, 26] Financial support and sponsorship Nil.
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